Drug Gastroenterology

Voquezna Triple Pak

Payments companies reported to CMS as associated with Voquezna Triple Pak. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$142Kassociated payments (2023-2025)
28clinicians with associated payments
1company reporting

By year

2023 $116K
2024 $26K

Payments reported as associated with Voquezna Triple Pak, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Gastroenterology (Internal Medicine) $123K
Physician Assistant $5,040
Adult Health (Nurse Practitioner) $5,010
Family $4,365
Nurse Practitioner $3,290
Acute Care (Nurse Practitioner) $1,680

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Voquezna Triple Pak

These are the largest totals companies reported as associated with Voquezna Triple Pak. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Shailja Shah San Diego, CA Gastroenterology (Internal Medicine) $18,000.00
Colin Howden Memphis, TN Gastroenterology (Internal Medicine) $11,100.00
Rena Yadlapati San Diego, CA Gastroenterology (Internal Medicine) $9,975.00
Kristle Lynch Philadelphia, PA Gastroenterology (Internal Medicine) $8,400.00
Michael Vaezi Nashville, TN Gastroenterology (Internal Medicine) $8,125.00
Ronnie Fass Cleveland, OH Gastroenterology (Internal Medicine) $7,750.00
Braden Kuo New York, NY Gastroenterology (Internal Medicine) $7,500.00
Linda Nguyen Stanford, CA Gastroenterology (Internal Medicine) $7,500.00
Joan Chen Ann Arbor, MI Gastroenterology (Internal Medicine) $7,000.00
Gary Falk Philadelphia, PA Gastroenterology (Internal Medicine) $7,000.00

Prescribed Voquezna Triple Pak?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.